Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Multispecies synbiotics alleviate dextran sulfate sodium (DSS)-induced colitis : Effects on clinical scores, intestinal pathology, and plasma biomarkers in male and female mice

Cai, Wenjie ; Pierzynowska, Kateryna LU orcid ; Stiernborg, Miranda ; Xu, Jingjing ; Nilsson, Ida AK ; Svensson, Ulla ; Melas, Philippe A. and Lavebratt, Catharina (2024) In Clinical Nutrition ESPEN 63. p.74-83
Abstract

Background: Inflammatory bowel disease (IBD) is characterized by recurrent inflammation of the gastrointestinal tract and has been linked to an imbalance in gut bacteria. Synbiotics, which combine probiotics and prebiotics, are emerging as potential IBD treatments. Aim: To examine the effects of four synbiotic formulations on intestinal inflammation and peripheral biomarkers in a rodent IBD model of both sexes. Methods: Colitis was induced in male and female C57BL/6 mice using 1% dextran sulfate sodium (DSS). Concurrently, a non-exposed control group was maintained. Starting on day 4 post-induction, DSS-exposed mice received one of four synbiotic preparations (Synbio1-4 composed of lactic acid bacteria, Bifidobacterium and dietary... (More)

Background: Inflammatory bowel disease (IBD) is characterized by recurrent inflammation of the gastrointestinal tract and has been linked to an imbalance in gut bacteria. Synbiotics, which combine probiotics and prebiotics, are emerging as potential IBD treatments. Aim: To examine the effects of four synbiotic formulations on intestinal inflammation and peripheral biomarkers in a rodent IBD model of both sexes. Methods: Colitis was induced in male and female C57BL/6 mice using 1% dextran sulfate sodium (DSS). Concurrently, a non-exposed control group was maintained. Starting on day 4 post-induction, DSS-exposed mice received one of four synbiotic preparations (Synbio1-4 composed of lactic acid bacteria, Bifidobacterium and dietary fibres), an anti-inflammatory drug used to treat IBD (mesalazine), or placebo (water) until day 14. Clinical symptoms and body weight were monitored daily. Blood samples (taken on days −3, 4, and 14, relative to DSS introduction), were used to analyze plasma biomarkers. At the end of the study, intestinal tissues underwent histological and morphological evaluation. Results: Compared to placebo, the Synbio1-, 2- and 3-treated groups had improved clinical scores by day 14. Synbio1 was the only preparation that led to clinical improvements to scores comparable to those of controls. The Synbio1-and 3-treated groups also demonstrated histological improvements in the colon. Plasma biomarker analyses revealed significant Synbio1-induced changes in plasma IL17A, VEGFD, and TNFRSF11B levels that correlated with improved clinical or histological scores. Sex-stratified analyses revealed that most therapeutic-like effects were more pronounced in females. Conclusion: Our findings underscore the potential therapeutic benefits of specific synbiotics for IBD management. However, further research is needed to validate these outcomes in human subjects.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Experimental colitis, Interleukin-17, Mesalazine, Prebiotic, Probiotic
in
Clinical Nutrition ESPEN
volume
63
pages
10 pages
publisher
Elsevier
external identifiers
  • scopus:85196648758
  • pmid:38923468
ISSN
2405-4577
DOI
10.1016/j.clnesp.2024.06.011
language
English
LU publication?
yes
id
bb68b9ba-32f8-4e46-a437-f8a68712971d
date added to LUP
2024-08-23 13:23:08
date last changed
2024-08-28 16:36:48
@article{bb68b9ba-32f8-4e46-a437-f8a68712971d,
  abstract     = {{<p>Background: Inflammatory bowel disease (IBD) is characterized by recurrent inflammation of the gastrointestinal tract and has been linked to an imbalance in gut bacteria. Synbiotics, which combine probiotics and prebiotics, are emerging as potential IBD treatments. Aim: To examine the effects of four synbiotic formulations on intestinal inflammation and peripheral biomarkers in a rodent IBD model of both sexes. Methods: Colitis was induced in male and female C57BL/6 mice using 1% dextran sulfate sodium (DSS). Concurrently, a non-exposed control group was maintained. Starting on day 4 post-induction, DSS-exposed mice received one of four synbiotic preparations (Synbio1-4 composed of lactic acid bacteria, Bifidobacterium and dietary fibres), an anti-inflammatory drug used to treat IBD (mesalazine), or placebo (water) until day 14. Clinical symptoms and body weight were monitored daily. Blood samples (taken on days −3, 4, and 14, relative to DSS introduction), were used to analyze plasma biomarkers. At the end of the study, intestinal tissues underwent histological and morphological evaluation. Results: Compared to placebo, the Synbio1-, 2- and 3-treated groups had improved clinical scores by day 14. Synbio1 was the only preparation that led to clinical improvements to scores comparable to those of controls. The Synbio1-and 3-treated groups also demonstrated histological improvements in the colon. Plasma biomarker analyses revealed significant Synbio1-induced changes in plasma IL17A, VEGFD, and TNFRSF11B levels that correlated with improved clinical or histological scores. Sex-stratified analyses revealed that most therapeutic-like effects were more pronounced in females. Conclusion: Our findings underscore the potential therapeutic benefits of specific synbiotics for IBD management. However, further research is needed to validate these outcomes in human subjects.</p>}},
  author       = {{Cai, Wenjie and Pierzynowska, Kateryna and Stiernborg, Miranda and Xu, Jingjing and Nilsson, Ida AK and Svensson, Ulla and Melas, Philippe A. and Lavebratt, Catharina}},
  issn         = {{2405-4577}},
  keywords     = {{Experimental colitis; Interleukin-17; Mesalazine; Prebiotic; Probiotic}},
  language     = {{eng}},
  pages        = {{74--83}},
  publisher    = {{Elsevier}},
  series       = {{Clinical Nutrition ESPEN}},
  title        = {{Multispecies synbiotics alleviate dextran sulfate sodium (DSS)-induced colitis : Effects on clinical scores, intestinal pathology, and plasma biomarkers in male and female mice}},
  url          = {{http://dx.doi.org/10.1016/j.clnesp.2024.06.011}},
  doi          = {{10.1016/j.clnesp.2024.06.011}},
  volume       = {{63}},
  year         = {{2024}},
}